Study Ranks Candidate Compounds Against N-Cadherin
Computational screening flagged BRD.K09587429 as the top discovery-stage candidate for targeting the N-cadherin HAV site, pending experimental validation.
Updated on Nov. 11, 2026 in Cancer

Researchers prioritized small-molecule candidates for the N-cadherin HAV site using an integrated multi-omics framework. The highest-ranked compound, BRD.K09587429, was identified as the leading discovery-stage candidate.
Why it matters
N-cadherin is a central effector of epithelial-to-mesenchymal transition, a process linked to invasion, metastasis and therapy resistance in cancer. Identifying candidates that could interfere with it offers a computational starting point for drug discovery.
Docking energies ranged from -8.1 to -5.9 kcal mol-1 across 20 compounds screened from LINCS L1000 profiles, with BRD.K09587429 scoring 0.656 on the composite ranking. A 100-ns molecular dynamics run gave an MM-PBSA binding-energy estimate of -24.58 ± 6.90 kcal mol-1, though these are predictions that have not been tested in the laboratory.
The details
The team screened compounds for concordant down-regulation of CDH2, SNAI1 and SNAI2, then docked them to the N-cadherin EC1 HAV pocket and compared results with a non-HAV control surface. Toxicity was assessed with a multi-task graph convolutional network trained on Tox21, and context-specific metabolic effects were modeled with Human1.
Timeline
Study results were recorded on November 11, 2026.
Health Landscape
The work follows a computational drug-discovery pattern that screens compounds against transcriptional signatures before any laboratory testing. Its candidates must still clear the same experimental validation hurdles that have constrained earlier N-cadherin-targeting efforts in cancer research.
At this discovery stage, the findings do not change treatment options or access for patients. Any candidate would need laboratory and clinical validation before it could affect how cancer is treated.
The takeaway
Computational screening can narrow the field of possible drug candidates, but predicted binding is only a first step. Experimental confirmation remains the decisive test for any compound identified this way.
Further reading
Explore more on Cancer research and treatment developments.
Source note: This article includes information reported by Nature.







